|
|
|
|
A CDMO’s success depends on execution, not just capacity. GRAM CEO shares how leadership, operational discipline, experienced teams, and tackling complex manufacturing challenges drive success in pharmaceutical manufacturing and commercialization.
|
|
|
|
|
Evaluating fill-finish CDMOs beyond cost and capacity ensures long-term success. Strategic focus on technical depth, scalability, and modern compliance reduces risk.
|
|
|
|
|
Effective sterile filling requires deep collaboration between equipment vendors and manufacturers. Explore how adaptable technologies and strategic partnerships help navigate Annex 1 compliance and technical hurdles to ensure the successful delivery of complex drug products.
|
|
|
|
|
The transition toward complex biologics and patient-centric delivery is redefining sterile manufacturing. Success now depends on adopting flexible production strategies and advanced technologies.
|
|
|
|
|
Cartridge drug delivery demands strict controls to guarantee dose accuracy. Early development and testing eliminate variability, prevent defects, and protect patient safety.
|
|
|
|
|
|
|
|
Insights From At CPHI Milan 2026: The Future Of Sterile Manufacturing
|
As biologics manufacturing evolves, Contract Development and Manufacturing Organizations (CDMOs) are becoming increasingly pivotal. At CPHI Milan, October 6 – 8, 2026, Grand River Aseptic Manufacturing (GRAM) will showcase its innovative capabilities, particularly in aligning manufacturing capacity and capabilities with clients’ long-term goals, at booth #8A26.
|
|
|
|
|
|
|
